Clinical Development 

Based on clinical and non-clinical data obtained from Ventaleon GmbH, AspiAir focuses on the development of inhaled medicines with acetylsalicylic acid.

Currently covered indications consist of acute coronary syndrome and acute/episodic migraine.

This development will include different medical devices for the delivery of inhaled acetylsalicylic acid to the airways.